Stock Events

Stock Events

IGC Pharma 

$0.28
88
+$0.03+11.6% Thursday 07:39

Statistics

Day High
0.28
Day Low
0.25
52W High
-
52W Low
-
Volume
29,103
Avg. Volume
-
Mkt Cap
25.91M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Apr 998
$0.02
Sep 996
$0.05
Jun 996
$0.06
Sep 994
$2.5
Jun 994
$2.5
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

15JunExpected
Q3 2025
Q4 2025
Next
-0.03
-0.02
-0.02
-0.02
Expected EPS
-0.025
Actual EPS
N/A

Financials

-560.27%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
2.54MRevenue
-14.24MNet Income

Analyst Ratings

$5.00Average Price Target
The highest estimate is 5.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IGC.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Corbus Pharmaceuticals
CRBP
Mkt Cap148.9M
Corbus Pharmaceuticals develops cannabinoid drugs for treating inflammatory and fibrotic diseases, overlapping with IGC's therapeutic areas.
Aurora Cannabis
ACB
Mkt Cap280.01M
Aurora Cannabis is a licensed producer and distributor of medical cannabis, competing with IGC in the cannabis product market.
Canopy Growth
CGC
Mkt Cap418.51M
Canopy Growth Corporation is a diversified cannabis and cannabinoid-based consumer product company, competing across several of IGC's target markets.
Tilray Brands
TLRY
Mkt Cap1.5B
Tilray is a global leader in cannabis research, cultivation, processing, and distribution, making it a direct competitor to IGC in the cannabis industry.
Cronos Group
CRON
Mkt Cap962.94M
Cronos Group is an innovative global cannabinoid company, with international production and distribution across five continents, competing with IGC in the global cannabis market.

About

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Show more...
CEO
ISIN
US45408X3089

Listings

F
DE
IGS1.F
BOATS
BOATS
IGC.BOATS
XASE
US
IGC

0 Comments

Share your thoughts

FAQ

What is IGC Pharma stock price today?▼
The current price of IGC.BOATS is $0.28 USD — it has increased by +11.6% in the past 24 hours. Watch IGC Pharma stock price performance more closely on the chart.
What is IGC Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange IGC Pharma stocks are traded under the ticker IGC.BOATS.
What is IGC Pharma market cap?▼
Today IGC Pharma has the market capitalization of 25.91M
When is the next IGC Pharma earnings date?▼
IGC Pharma is going to release the next earnings report on June 15, 2026.
What were IGC Pharma earnings last quarter?▼
IGC.BOATS earnings for the last quarter are -0.02 USD per share, whereas the estimation was -0.02 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is IGC Pharma revenue for the last year?▼
IGC Pharma revenue for the last year amounts to 2.54M USD.
What is IGC Pharma net income for the last year?▼
IGC.BOATS net income for the last year is -14.24M USD.
Does IGC Pharma pay dividends?▼
Yes, IGC.BOATS dividends are paid semi-annual. The last dividend per share was 0.02 USD. As of today, Dividend Yield (FWD)% is 0%.
When did IGC Pharma complete a stock split?▼
IGC Pharma has not had any recent stock splits.